2016
DOI: 10.1007/s00228-016-2171-5
|View full text |Cite
|
Sign up to set email alerts
|

Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials

Abstract: ERAs therapy is not significantly associated with increased all-cause death, but there are more cardiovascular events and edema or fluid retention, anemia, and liver enzymes disorder. Large clinical randomized controlled studies are needed to further confirm the safety of the clinical application of ERAs.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
8
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(8 citation statements)
references
References 53 publications
0
8
0
Order By: Relevance
“…PH due to left sided heart disease) were investigated in four studies [ 20 , 34 , 43 , 44 ] while patients with PAH were examined alongside other diseases (e.g. heart failure, prostate cancer) in two studies [ 45 , 58 ].…”
Section: Resultsmentioning
confidence: 99%
See 4 more Smart Citations
“…PH due to left sided heart disease) were investigated in four studies [ 20 , 34 , 43 , 44 ] while patients with PAH were examined alongside other diseases (e.g. heart failure, prostate cancer) in two studies [ 45 , 58 ].…”
Section: Resultsmentioning
confidence: 99%
“…With a number of exceptions [ 17 , 20 , 24 , 25 , 34 , 35 , 39 – 41 , 45 , 47 , 54 , 58 , 59 , 61 , 62 , 64 ], most studies investigated treatments targeting all three pathways. All the approved treatments (ERA, PDE-5Is, PRAs, prostacyclin and sGCS) were investigated in nine recent studies [ 27 , 30 , 38 , 42 , 46 , 48 , 57 , 63 , 67 ].…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations